Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
Rhea-AI Summary
Syndax (Nasdaq: SNDX) will report third quarter 2025 financial results and provide a business update on Monday, November 3, 2025. Management will host a conference call and live audio webcast at 4:30 p.m. ET the same day.
Investors can access the live webcast and slides via the Investors & Events page on the company website or join by phone using Conference ID: Syndax3Q25 (Domestic: 800-590-8290; International: 240-690-8800). A replay will be available on the Investors site about 24 hours after the call and remain accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – SNDX
On the day this news was published, SNDX declined 3.10%, reflecting a moderate negative market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $38M from the company's valuation, bringing the market cap to $1.20B at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 3, 2025.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 3, 2025.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax3Q25
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-3q25.open-exchange.net
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When will Syndax (SNDX) report third quarter 2025 results?
What time is the Syndax (SNDX) earnings call on November 3, 2025?
How can I access the Syndax (SNDX) November 3, 2025 webcast and slides?
What is the Syndax (SNDX) conference call dial-in and conference ID for Q3 2025?
Will there be a replay of the Syndax (SNDX) Q3 2025 earnings call?
Where is the Syndax (SNDX) live webcast link for the November 3, 2025 call?
